Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2022

Open Access 01-02-2022 | Tuberculosis | The Global Epidemic (S Vermund, Section Editor)

COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa

Authors: Quarraisha Abdool Karim, Cheryl Baxter

Published in: Current HIV/AIDS Reports | Issue 1/2022

Login to get access

Abstract

Purpose of Review

To describe how mitigation measures against COVID-19 have impacted HIV and TB research in South Africa.

Recent Findings

South Africa has the highest number of COVID-19 (34%) cases in Africa, accounting for 43% of all reported COVID-19-related deaths on the continent. The country accounts for 20% of all people living with HIV and ranked third in the world for new TB infections in 2019.

Summary

While South Africa’s investments in its HIV and TB responses enabled it to pivot rapidly to respond to the emerging COVID-19 epidemic, it negatively impacted the HIV and TB response through temporary suspension of research, diversion of key resources for HIV and TB control, and patient access to health care facilities; the full extent of this has yet to emerge. Success in integrating responses to the colliding epidemics could potentially enhance survival outcomes and ensure gains made to date in HIV and TB are not reversed and we stay on track toward achieving the UN 2030 Sustainable Development Goals.
Literature
1.
2.
3.
Bradshaw D, Laubscher R, Dorrington R, Groenewald P, Moultrie T: Report on weekly deaths in South Africa. Available from: (Accessed 28 May 2021). Edited by. Burden of Disease Unit, Pretoria: South African Medical Research Council; 2021.
4.
UNAIDS: Ending AIDS: progress towards the 90–90–90 targets. Edited by. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2017.
5.
6.
7.
8.
9.
Neethling I, Groenewald P, Bradshaw D, Day C., Laubscher R: Burden of disease. In District Health Barometer 2019/2020. Edited by Naomi Massyn CD, Noluthando Ndlovu, Thesandree Padayachee: Health Systems Trust; 2020.
10.
11.
Pillay S, Giandhari J, Tegally H, Wilkinson E, Chimukangara B, Lessells R, Moosa Y, Mattison S, Gazy I, Fish M, et al. Whole genome sequencing of SARS-CoV-2: adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic. Genes (Basel) 2020;11.
12.
•. Cleemput S, Dumon W, Fonseca V, Abdool Karim W, Giovanetti M, Alcantara LC, Deforche K, de Oliveira T. Genome detective coronavirus typing tool for rapid identification and characterization of novel coronavirus genomes. Bioinformatics. 2020;36:3552–3555. Establishing protocols for the identification of SARS-CoV-2.
13.
Baxter C, AbdoolKarim Q, AbdoolKarim SS. Identifying SARS-CoV-2 infections in South Africa: balancing public health imperatives with saving lives. Biochem Biophys Res Commun. 2021;538:221–5.CrossRef
14.
AbdoolKarim Q, AbdoolKarim SS. COVID-19 affects HIV and tuberculosis care. Science. 2020;369:366–8.CrossRef
15.
World Health Organisation: WHO: access to HIV medicines severely impacted by COVID-19 as AIDS response stalls. Edited by; 2020.
16.
Department of Health: Media statement: COVID-19 impacts on health services in Gauteng. Edited by; 2020.
17.
Doherty M: The global impact of COVID-19 on essential health services including HIV, tuberculosis, hepatitis, and sexually transmitted infections. In AIDS 2020. Edited by. Virtual; 2020.
18.
World Health organisation: The cost of inaction: COVID-19-related service disruptions could cause hundreds of thousands of extra deaths from HIV. Edited by. Geneva, Switzerland: World Health Organisation; 2020.
19.
20.
21.
••. Madhi SA, Gray GE, Ismail N, Izu A, Mendelson M, Cassim N, Stevens W, Venter F. COVID-19 lockdowns in low- and middle-income countries: success against COVID-19 at the price of greater costs. S Afr Med J. 2020;110:724–726. Providing evidence on how Covid-19 restrictions led to disruptions in TB and HIV services during lockdown.
22.
••. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, Jeewa A, Bottomley C, Lewis L, Baisley K, et al. The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. Lancet HIV. 2021;8:e158-e165. Analysis of data showing declines in HIV testing and ART initiation during lockdown.
23.
Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, Mills EJ, Gross R. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11:167–74.CrossRef
24.
Brody JK, Rajabiun S, Strupp Allen HJ, Baggett T. Enhanced telehealth case management plus emergency financial assistance for homeless-experienced people living with HIV during the COVID-19 pandemic. Am J Public Health. 2021;111:835–8.CrossRef
25.
Hoagland B, Torres TS, Bezerra DRB, Benedetti M, Pimenta C, Veloso VG, Grinsztejn B. High acceptability of PrEP teleconsultation and HIV self-testing among PrEP users during the COVID-19 pandemic in Brazil. Braz J Infect Dis. 2021;25:101037.CrossRef
26.
Hochstatter KR, Akhtar WZ, Dietz S, Pe-Romashko K, Gustafson DH, Shah DV, Krechel S, Liebert C, Miller R, El-Bassel N, et al. Potential influences of the COVID-19 pandemic on drug use and HIV care among people living with HIV and substance use disorders: experience from a pilot mhealth intervention. AIDS Behav. 2021;25:354–9.CrossRef
27.
28.
29.
Loveday M, Cox H, Evans D, Furin J, Ndjeka N, Osman M. Naidoo For The National Tb Think Tank “Optimising Tb Treatment Outcomes” Task Team K: Opportunities from a new disease for an old threat: extending COVID-19 efforts to address tuberculosis in South Africa. S Afr Med J. 2020;110:1160–7.CrossRef
30.
31.
Mirzaei H, McFarland W, Karamouzian M, Sharifi H: COVID-19 among people living with HIV: a systematic review. AIDS and behavior 2020:1–8.
32.
••. Davies M-A. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa. medRxiv. 2020:2020.2007.2002.20145185. Cohort study shoowing increased risk of mortality among HIV-infected individuals.
33.
Davies M: Western Cape: Covid-19 and HIV / tuberculosis. Edited by; 2020. vol 2020.]
34.
•. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo RM, Morton CE, Bacon SCJ, Inglesby P, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 2021;8:e24-e32. This cohort study shows an increased risk of mortality among HIV-infected individuals.
35.
•. Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al.: SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021, 592:277–282. Providing evidence showing persistance viral replication leads to mutations consistent with variants of concern
36.
••. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo H-H, Boucau J, Bowman K, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. New England Journal of Medicine 2020, 383:2291–2293. Shows that persistant viral replication gives rise to variants of concern.
37.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397:99–111.CrossRef
38.
39.
40.
Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, Mlisana K, Bhiman JN, von Gottberg A, Walaza S, et al. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med. 2021;27:440–6.CrossRef
Metadata
Title
COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
Authors
Quarraisha Abdool Karim
Cheryl Baxter
Publication date
01-02-2022
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2022
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00588-5

Other articles of this Issue 1/2022

Current HIV/AIDS Reports 1/2022 Go to the issue

Central Nervous System and Cognition (SS Spudich, Section Editor)

Emerging Single-cell Approaches to Understand HIV in the Central Nervous System

The Global Epidemic (S Vermund, Section Editor)

PEPFAR’s Role in Protecting and Leveraging HIV Services in the COVID-19 Response in Africa

The Global Epidemic (S Vermund, Section Editor)

HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups

The Global Epidemic (SH Vermund, Section Editor)

Intersecting Pandemics of HIV and SARS-CoV-2: Commentary on the Special Issue

The Global Epidemic (S Vermund, Section Editor)

Adventures in COVID-19 Policy Modeling: Education Edition

The Global Epidemic (S Vermund, Section Editor)

Social Determinants of Disease: HIV and COVID-19 Experiences
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits